- Home
- VMEO vs NRIX Comparison
VMEO vs NRIX Comparison
Compare VMEO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- NRIX
- Stock Information
- Founded
- VMEO 2004
- NRIX 2009
- Country
- VMEO United States
- NRIX United States
- Employees
- VMEO N/A
- NRIX N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- NRIX Health Care
- Exchange
- VMEO Nasdaq
- NRIX Nasdaq
- Market Cap
- VMEO 832.5M
- NRIX 1.1B
- IPO Year
- VMEO N/A
- NRIX 2020
- Fundamental
- Price
- VMEO $4.89
- NRIX $10.45
- Analyst Decision
- VMEO Buy
- NRIX Strong Buy
- Analyst Count
- VMEO 3
- NRIX 17
- Target Price
- VMEO $8.67
- NRIX $30.82
- AVG Volume (30 Days)
- VMEO 1.2M
- NRIX 1.0M
- Earning Date
- VMEO 05-05-2025
- NRIX 04-14-2025
- Dividend Yield
- VMEO N/A
- NRIX N/A
- EPS Growth
- VMEO 19.88
- NRIX N/A
- EPS
- VMEO 0.16
- NRIX N/A
- Revenue
- VMEO $417,006,000.00
- NRIX $54,549,000.00
- Revenue This Year
- VMEO $4.16
- NRIX N/A
- Revenue Next Year
- VMEO $6.76
- NRIX $3.20
- P/E Ratio
- VMEO $33.69
- NRIX N/A
- Revenue Growth
- VMEO N/A
- NRIX N/A
- 52 Week Low
- VMEO $3.43
- NRIX $10.21
- 52 Week High
- VMEO $7.90
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- VMEO 29.44
- NRIX 28.88
- Support Level
- VMEO $5.31
- NRIX $10.21
- Resistance Level
- VMEO $5.34
- NRIX $13.10
- Average True Range (ATR)
- VMEO 0.16
- NRIX 0.79
- MACD
- VMEO -0.02
- NRIX -0.12
- Stochastic Oscillator
- VMEO 7.65
- NRIX 5.48
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.